Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Hanwha Chemical Corporation (KOSPI: 09830) today announced that they have entered into an exclusive global agreement to develop and commercialize a candidate biosimilar form of Enbrel® (etanercept). Under the terms of the agreement, Hanwha Chemical Corporation, through ...

(American Academy of Sleep Medicine) Large corporations could save millions of dollars in lost productivity by screening and treating high-risk employees for obstructive sleep apnea, suggests a research abstract that will be presented Monday, June 13, in Minneapolis, Minn., at SLEEP 2011, the 25th Anniversary Meeting of the Associated Professional ...

Adolor Corporation (NasdaqGM: ADLR) today announced that it has completed enrollment in its Phase 2 clinical evaluation of ADL5945 in chronic, non-cancer pain patients with opioid-induced constipation (OIC). Adolor is conducting two Phase 2 studies of ADL5945 in OIC patients in parallel. The first study is evaluating two doses ...

Animas Corporation announced today the receipt of CE Mark approval for Animas® Vibe™, the first and only continuous glucose monitoring (CGM)-enabled insulin pump system with Dexcom G4™ CGM technology. Animas® Vibe™ brings together the unique features of an Animas® insulin pump and the convenience of Dexcom CGM, which is ...

CEL-SCI Corporation (NYSE Amex: CVM) today announced the positive results of efficacy studies in mice of L.E.A.P.S.TM (Ligand Epitope Antigen Presentation System) H1N1 activated dendritic cells (DCs) to treat the H1N1 virus. Scientists found that H1N1-infected mice treated with LEAPS-H1N1 DCs showed a survival advantage over mice treated with control ...

CEL-SCI Corporation (NYSE AMEX: CVM) announced today that it has received approval to begin enrollment of patients in its Phase III clinical trial of Multikine® from the Polish Minister of Health. This approval marks a very important milestone, namely that all nine countries in the study have now given official ...

Volcano Corporation (NASDAQ: VOLC), the leading developer and manufacturer of precision guided therapy tools designed to enhance the treatment of coronary and peripheral vascular disease, announced the signing of a supply agreement with ev3, a Covidien company, under which Volcano will supply its proprietary Intravascular Ultrasound (IVUS) technology for ...

CEL-SCI Corporation (NYSE AMEX: CVM) announced today that the Department of Health, Taiwan has issued an approval letter that allows enrollment of patients to begin in Taiwan in the Phase III clinical trial of Multikine®. The approval letter was issued by the Department of Health after manufacturing and stability data ...

MINNEAPOLIS, May 3, 2011 /- Techne Corporation's (NASDAQ: TECH ) consolidated pretax net earnings for the quarter ended March 31, 2011 increased 9.5% to $45.4 million compared with $41.4 million for the quarter ended March 31, 2010, mainly as a result of increased sales and foreign exchange transaction ...

CEL-SCI Corporation (NYSE AMEX: CVM) announced today that it has received approval to begin enrollment of patients in its Phase III clinical trial of Multikine® in India from the Directorate General of Health Services Office of Drug Controller General (India) - the Indian equivalent of the FDA. India is an ...

Reverse Medical Corporation announced today that it has received CE Mark (Conformité Européenne) for its ReFlex™ A+ Catheter for intracranial distal access, delivery and aspiration. The ReFlex A+ Catheter is uniquely designed to provide endovascular intracranial access during interventional neurovascular procedures. The CE Mark allows the Company to market ReFlex™ ...

NeuroLogica Corporation announced the receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the world's first portable, full body, multi-slice CT scanner, the BodyTom™. The BodyTom™ is the newest offering in NeuroLogica's portable computed tomography imaging line. BodyTom™ is a completely portable, full body, 32 ...